Biomolecules & Therapeutics : eISSN 2005-4483 / pISSN 1976-9148

Download original image
Fig. 2. Screening of the FDA-approved drugs against SARS-CoV-2 infection in Vero E6 cells. The plaque reduction assay was performed with 12 FDA-approved drugs. SARS-CoV-2 was mixed with 10 µM or the indicated concentrations of each compound, and then, the mixture was used to infect Vero E6 cells for 1 h. The supernatant was removed and overlaid with 3 mL DMEM/F12 medium containing 2% Oxoid agar and TPCK (1 µg/mL)-treated trypsin. After a 72 h infection, the plaques were observed by staining with crystal violet. These data show only 5 representatives of the 18 FDA-approved drugs. (A) Effect of atovaquone (10 µM) and β-estradiol 3-benzoate (10 µM) on SARS-CoV-2 infection. (B) Effect of abiraterone acetate (10 µM) on SARS-CoV-2 infection. (C) Effect of digoxin on SARS-CoV-2 infection at each concentration.
Biomolecules & Therapeutics 2022;30:427~434 https://doi.org/10.4062/biomolther.2022.037
© Biomolecules & Therapeutics